Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
NCT ID: NCT00005096
Last Updated: 2017-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
19 participants
INTERVENTIONAL
1999-12-31
2002-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients
NCT00714376
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
NCT00017563
Docetaxel in Treating Patients With Stage IV Prostate Cancer
NCT00003781
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
NCT00003858
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00416533
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment continues for 2-6 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Docetaxel
Docetaxel given via iv at determined dose once a week for 4 weeks
docetaxel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
docetaxel
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Evidence of serious active infection
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Rhone-Poulenc Rorer
INDUSTRY
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary-Ellen Taplin, MD
Taplin, Mary-Ellen
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary-Ellen Taplin, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DFCI-99193
Identifier Type: -
Identifier Source: secondary_id
NCI-G00-1757
Identifier Type: -
Identifier Source: secondary_id
99-193
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.